Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).

Autor: Rigopoulos D; 1st Department of Dermatology-Venereology, University of Athens, Athens, Greece., Tampouratzi E; Dermatological Department, Tzaneio General Hospital, Piraeus, Greece., Angelakopoulos C; Department of Dermatology, Athens Naval Hospital, Athens, Greece., Apalla Z; 2nd Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece., Barkis I; Private Physician, Athens, Greece., Georgiou S; Department of Dermatology, Medical School, General University Hospital, University of Patras, Patras, Greece., Delli F; State Dermatology Department, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece., Drosos A; Department of Dermatology, General Hospital of Xanthi, Xanthi, Greece., Zafiriou E; Department of Dermatology, University General Hospital Larissa, University of Thessaly, Larissa, Greece., Katsantonis J; Dermatological Department, Tzaneio General Hospital, Piraeus, Greece., Lazaridou E; 2nd Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece., Panagakis P; Department of Dermatology and Venereology NHS, Andreas Syggros Hospital, Athens, Greece., Papadavid E; 2nd Department of Dermatology and Venereology, Attikon University Hospital, Athens, Greece., Papakonstantis M; Clinic of Dermatology, 401 General Military Hospital of Athens, Athens, Greece., Roussaki-Schulze AV; Department of Dermatology, University General Hospital Larissa, University of Thessaly, Larissa, Greece., Sotiriou E; 1st Dermatology Department, Medical School, Aristotle University, Thessaloniki, Greece., Anastasiadis G; Department of Dermatology, General Hospital of Athens 'Evangelismos', Athens, Greece., Chasapi V; Department of Dermatology and Venereology NHS, Andreas Syggros Hospital, Athens, Greece., Sfaelos K; Department of Dermatology, LEO Pharma Hellas, Chalandri, Greece., Ioannides D; 1st Dermatology Department, Medical School, Aristotle University, Thessaloniki, Greece.
Jazyk: angličtina
Zdroj: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Jun; Vol. 38 (6), pp. 1121-1130. Date of Electronic Publication: 2024 Feb 03.
DOI: 10.1111/jdv.19816
Abstrakt: Background: Despite that brodalumab's efficacy and safety have been assessed in randomized clinical trials, real-life data remain scarce. BrIDGE was an observational, prospective, single-cohort, multicentre study that recruited patients with moderate-to severe plaque psoriasis in Greece.
Objectives: The primary objective was to assess the proportion of patients who achieved Psoriasis Area and Severity Index (PASI)100 after 24 weeks. Other endpoints included: the maintenance of PASI90/100 through to 104 weeks, the short-term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12-16 weeks and time to complete clearance. Moreover, we explored the change in quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab.
Methods: Two hundred patients who were initiating treatment with or switching to brodalumab, were recruited. Analyses were conducted using the as observed data and three imputation approaches were also applied for the missing data (last observation carried forward, 'worst case' and 'best case' scenario). Continuous variables were reported using summary statistics, whereas categorical variables were reported in frequency tables.
Results: Based on the 'as observed data', 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104. In total, 70.2%, 47.5% and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12-16. With respect to sPGA status 82.8%, 89.2% and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52 and 104, respectively. The time to achieve PASI100 at Weeks 12-16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104. Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Adherence to treatment was equal to 98.9%.
Conclusions: Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate-to-severe psoriasis patients.
(© 2024 European Academy of Dermatology and Venereology.)
Databáze: MEDLINE
Externí odkaz: